Ocugen Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Ocugen de 34% y 54.5% respectivamente, mientras que el BPA crecerá en un 32.4% al año.

Información clave

19.3%

Tasa de crecimiento de los beneficios

16.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.7%
Tasa de crecimiento de los ingresos	57.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	15 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Ocugen: FDA Lifts Clinical Hold As Shares Sink - It May Be Worth Staying The Course

Feb 24

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:OCGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	21	-78	N/A	N/A	1
12/31/2025	N/A	-82	N/A	N/A	3
12/31/2024	1	-60	N/A	N/A	3
3/31/2024	7	-58	-66	-54	N/A
12/31/2023	6	-63	-73	-62	N/A
9/30/2023	3	-82	-77	-68	N/A
6/30/2023	3	-90	-76	-68	N/A
3/31/2023	3	-86	-69	-63	N/A
12/31/2022	2	-87	-65	-60	N/A
9/30/2022	N/A	-74	-59	-56	N/A
6/30/2022	N/A	-63	-52	-50	N/A
3/31/2022	N/A	-69	-59	-58	N/A
12/31/2021	N/A	-58	-49	-48	N/A
9/30/2021	N/A	-48	-41	-39	N/A
6/30/2021	N/A	-47	-35	-34	N/A
3/31/2021	0	-38	-16	-15	N/A
12/31/2020	0	-34	-15	-15	N/A
6/30/2020	0	-30	-19	-19	N/A
3/31/2020	N/A	-18	-19	-19	N/A
12/31/2019	N/A	-20	-17	-17	N/A
9/30/2019	N/A	-39	-11	-11	N/A
6/30/2019	N/A	-18	-12	-12	N/A
3/31/2019	N/A	-19	-12	-12	N/A
12/31/2018	N/A	-18	-12	-12	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que OCGN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que OCGN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que OCGN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (57.3% al año) de OCGN crezcan más rápidamente que los del mercado US (8.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (57.3% al año) de OCGN crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de OCGN se prevé que sea elevada dentro de 3 años.

Ocugen Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 19% to US$6.33

Price target increased by 13% to US$4.50

Forecast to breakeven in 2026

Price target decreased by 17% to US$4.00

Price target decreased by 19% to US$3.90

Consensus revenue estimates fall by 58%

Recent updates

Law Offices of Howard G. Smith Alleges Lawsuit Against Ocugen, Inc

Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410

Ocugen, Inc., Annual General Meeting, Jun 28, 2024

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

New major risk - Share price stability

Price target increased by 19% to US$6.33

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

New minor risk - Share price stability

Price target increased by 13% to US$4.50

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Insufficient new directors

Forecast to breakeven in 2026

Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Price target decreased by 17% to US$4.00

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. announced delayed 10-Q filing

Price target decreased by 19% to US$3.90

Independent Director recently bought US$100k worth of stock

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Ocugen, Inc. has completed a Follow-on Equity Offering.

Consensus revenue estimates fall by 58%

No longer forecast to breakeven

Co-Founder exercised options and sold US$75k worth of stock

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Co-Founder notifies of intention to sell stock

Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met

Forecast to breakeven in 2025

Co-Founder notifies of intention to sell stock

Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

High number of new directors

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Co-Founder exercised options and sold US$115k worth of stock

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology

Ocugen announces peer-reviewed publication on COVID-19 vaccine

Ocugen, Inc. Announces Board Changes

Price target decreased to US$7.00

Ocugen initiated with Buy at Mizuho citing favorable setup ahead of key readout

Consensus forecasts updated

No longer forecast to breakeven

Consensus forecasts updated

Ocugen Q2 2022 Earnings Preview

Ocugen, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Ocugen: A First Take

Co-Founder exercised options and sold US$359k worth of stock

Ocugen in renewed focus as FDA wants COVID boosters to fight Omicron variant

Ocugen, Inc. Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2 18 in the Lancet Infectious Diseases

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin (Bbv152)

Co-Founder exercised options and sold US$199k worth of stock